NCT03705533View on ClinicalTrials.gov

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

December 16, 2018

Study Completion Date

December 19, 2018

Conditions

Bioequivalence

Interventions

DRUG

Telmisartan

Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.

DRUG

Micardis

Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.

Trial Locations (1)

H3P 3P1

Algorithme Pharma, An Altasciences Company, Mount Royal

All Listed Sponsors

collaborator

Algorithme Pharma, An Altasciences Company

UNKNOWN

lead

Pharmtechnology LLC

INDUSTRY

NCT03705533 - Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State | Biotech Hunter | Biotech Hunter